Composition for improving brain blood circulation
The invention relates to medicine, namely to drugs that improve blood circulation in the brain. The essence of the invention is that the composition for improvement of brain blood circulation contains Vinpocetine and piracetam as active ingredients and put into a hard gelatin capsule, and the target additives contains sugar, milk and calcium stearate in the following ratio of components, g per 1 capsule: Vinpocetine 0,0045-0,0055, piracetam 0,3600-0,4400, sugar, milk 0,0990 - 0,1210, calcium stearate 0,0045-0,0055. The technical result is the creation of a capsulated form of a drug that has the combined effect of Vinpocetine and piracetam and expansion of the range of medicines for improvement of brain blood circulation. table 2. The invention relates to medicine, specifically to drugs that improve blood circulation in the brain.In recent years, widespread in medical practice has received (3





notice to improve cerebral circulation, comprising an effective amount of Vinpocetine and piracetam as active substances and additives target, characterized in that it is enclosed in a hard gelatin capsule and the target additives contains sugar, milk and calcium stearate in the following ratio of components, g per 1 capsule: Vinpocetine - 0,0045-0,0055, piracetam - 0,3600-0,4400, sugar, milk 0,0990-0,1210, calcium stearate 0,0045-0,0055.
Same patents:
The invention relates to pharmaceutical industry and medicine and relates to products containing derivatives of gamma-aminobutyric acid and affecting the cardiovascular system
The invention relates to the pharmaceutical industry and relates to a pharmaceutical composition comprising (S)-N-ethyl-3-[1-dimethylamino)ethyl]-N-methylphenylcarbinol and antioxidant, have higher stability as well as devices for transdermal injection
The invention relates to medicine, namely to pharmacology and psychiatry
The invention relates to new derivatives of benzothiadiazole, benzoxazoles and benzodiazines formula I in free base form or in the form of a pharmaceutically acceptable acid salt additive that can be used as an anxiolytic drug in the treatment of any condition, which is associated with increased endogenous levels of CRF or in which violated the regulation of the hPa system (hypothalamic - pituitary), or various diseases that are caused by CRF1or the manifestation of which contributes CRF1such as arthritis, asthma, allergies, anxiety, depression, etc
The invention relates to a new one with selective affinity to T6receptors, pyrazolo[1,5-a]pyrimidines and pyrazolo[1,5-a]triazines General formula I, where X denotes a =C(R4)- or =N-, R1denotes phenyl, optionally substituted by one or more radicals of lower alkyl, halogen, lower alkoxygroup, tolyl, pyridyl, naphthyl or thiophenyl, R2denotes hydrogen, (ness.)alkyl, (ness.)thioalkyl or hydroxy(ness.) alkoxygroup, R3denotes amino(ness.)alkylamino, di(ness.)alkylamino, piperazinil, optionally substituted by one or more radicals, lower alkyl, benzyl, phenyl or hydroxy(NISS
Colostrinin and its application // 2217152
The invention relates to medicine and can be used to prevent degeneration of nerve cells and accelerate the regeneration of nerve cells
The invention relates to pharmaceutical
The invention relates to tablets comprising a Central, rounded or spherical core diameter of 250-355 µm (45-60 mesh), the coating film of the water soluble polymer and Itraconazole, and a layer of protective polymer coatings for pharmaceutical dosage form, as well as to a method for the specified bean
The invention relates to medicine, namely to create drugs with complex medical and preventive action, and for the composition for the prevention of atherosclerosis, cardiovascular disease and maintenance therapy of viral diseases
The invention relates to medicine, namely to create drugs with complex medical and preventive action, and for the composition for the prevention of atherosclerosis, cardiovascular disease and maintenance therapy of viral diseases
The invention relates to the pharmaceutical industry and relates to a mixture of primary fatty acids derived from sugar-cane wax
The solution cyclosporine // 2216342
The invention relates to the field of medicine and for the solution of cyclosporine
The invention relates to chemical-pharmaceutical industry, namely to medicinal drug for the treatment of degenerative dystrophic diseases of joints - osteoarthritis, made in the form of a capsule containing chondroitin sulfate, stearic acid or calcium stearate and lactose
Stable pharmaceutical composition for oral administration containing substituted pyridinesulfonamide // 2216321
The invention relates to the field of pharmaceutical industry and relates to improved pharmaceutical compositions for oral administration containing substituted pyridinesulfonamide and a carrier comprising a polymer with vinylpyrrolidone links or a copolymer of vinylpyrrolidone and vinyl acetate, located mainly in the form of a capsule, coated, containing a mixture of substituted pyridinesulfonamide and polymer
The invention relates to new imidazolidine formulas (I) and (II) in which a is a =N-CR=CR-CR=, =CR-N=CR-CR=, =CR-CR=N=CR or = CR-CR= CR-N= ; B represents-NR-C(R)2-C(R)2-C(R)2C(R)2-NR-C(R)2-C(R)2, -C(R)2-C(R)2-NR-C(R)2or C(R)2-C(R)2-C(R)2-NR, where R is hydrogen, R1is hydrogen, unsubstituted or substituted C1-20-alkyl, C1-20-alkylene-NR3-Q-X-R4where Q represents-CO-or-SO2-, X is a simple bond, -O - or-NR3and R4- aryl, heteroaryl, heterocyclyl or1-20-alkyl or C2-20alkenyl